首页> 外文期刊>Expert review of clinical immunology >Kidney transplantation, bioengineering and regeneration: an originally immunology-based discipline destined to transition towards ad hoc organ manufacturing and repair
【24h】

Kidney transplantation, bioengineering and regeneration: an originally immunology-based discipline destined to transition towards ad hoc organ manufacturing and repair

机译:肾脏移植,生物工程和再生:最初是基于免疫学的学科,注定要过渡到临时器官的制造和修复

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Kidney transplantation (KT), as a modality of renal replacement therapy (RRT), has been shown to be both economically and functionally superior to dialysis for the treatment of end-stage renal disease (ESRD). Progress in KT is limited by two major barriers: a) a chronic and burgeoning shortage of transplantable organs and b) the need for chronic immunosuppression following transplantation. Although ground-breaking advances in transplant immunology have improved patient survival and graft durability, a new pathway of innovation is needed in order to overcome current obstacles. Regenerative medicine (RM) holds the potential to shift the paradigm in RRT, through organ bioengineering. Manufactured organs represent a potentially inexhaustible source of transplantable grafts that would bypass the need for immunosuppressive drugs by using autologous cells to repopulate extracellular matrix (ECM) scaffolds. This overview discusses the current status of renal transplantation while reviewing the most promising innovations in RM therapy as applied to RRT.
机译:肾脏移植(KT)作为肾脏替代疗法(RRT)的一种形式,已被证明在经济和功能上均优于透析治疗终末期肾脏疾病(ESRD)。 KT的进展受到两个主要障碍的限制:a)可移植器官的长期和迅速短缺,以及b)移植后需要进行长期免疫抑制。尽管移植免疫学的突破性进展提高了患者的存活率和移植物的耐用性,但仍需要一条新的创新途径来克服当前的障碍。再生医学(RM)具有通过器官生物工程改变RRT范式的潜力。人造器官代表了潜在的取之不尽的可移植移植物来源,通过使用自体细胞重新填充细胞外基质(ECM)支架,可以绕过对免疫抑制药物的需求。本概述讨论了肾移植的现状,同时回顾了应用于RRT的RM治疗中最有希望的创新。

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号